

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Papapetropoulos Spyros</u> _____ (Last) (First) (Middle) 200 GREENHILL ROAD _____ (Street) EASTWOOD, SOUTH C3 5063 AUSTRALIA _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 07/01/2024	3. Issuer Name and Ticker or Trading Symbol <u>BIONOMICS LIMITED/FI [BNOX]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Executive Officer	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares ⁽¹⁾	5,999,940	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Option (right to buy)	12/16/2023	12/16/2028	Ordinary Shares	6,766,754	0.0321	D	
Option (right to buy)	03/16/2024	03/16/2029	Ordinary Shares	1,691,688	0.0321	D	
Option (right to buy)	06/16/2024	06/16/2029	Ordinary Shares	1,691,689	0.0321	D	
Option (right to buy)	(2)	09/16/2029	Ordinary Shares	1,691,688	0.0321	D	
Option (right to buy)	(3)	12/16/2029	Ordinary Shares	1,691,689	0.0321	D	
Option (right to buy)	(4)	03/16/2030	Ordinary Shares	1,691,688	0.0321	D	
Option (right to buy)	(5)	06/16/2030	Ordinary Shares	1,691,689	0.0321	D	
Option (right to buy)	(6)	09/16/2030	Ordinary Shares	1,691,688	0.0321	D	
Option (right to buy)	(7)	12/16/2030	Ordinary Shares	1,691,689	0.0321	D	
Option (right to buy)	(8)	03/16/2031	Ordinary Shares	1,691,688	0.0321	D	
Option (right to buy)	(9)	06/16/2031	Ordinary Shares	1,691,689	0.0321	D	
Option (right to buy)	(10)	09/16/2031	Ordinary Shares	1,691,688	0.0321	D	
Option (right to buy)	(11)	12/16/2031	Ordinary Shares	1,691,688	0.0321	D	

Explanation of Responses:

- Some Ordinary Shares are represented by American Depositary Shares.
- Granted on December 16, 2022. Vesting to occur on September 16, 2024, provided Mr. Papapetropoulos is still employed on such date.
- Granted on December 16, 2022. Vesting to occur on December 16, 2024, provided Mr. Papapetropoulos is still employed on such date.
- Granted on December 16, 2022. Vesting to occur on March 16, 2025, provided Mr. Papapetropoulos is still employed on such date.
- Granted on December 16, 2022. Vesting to occur on June 16, 2025, provided Mr. Papapetropoulos is still employed on such date.
- Granted on December 16, 2022. Vesting to occur on September 16, 2025, provided Mr. Papapetropoulos is still employed on such date.
- Granted on December 16, 2022. Vesting to occur on December 16, 2025, provided Mr. Papapetropoulos is still employed on such date.

- 8. Granted on December 16, 2022. Vesting to occur on March 16, 2026, provided Mr. Papapetropoulos is still employed on such date.
- 9. Granted on December 16, 2022. Vesting to occur on June 16, 2026, provided Mr. Papapetropoulos is still employed on such date.
- 10. Granted on December 16, 2022. Vesting to occur on September 16, 2026, provided Mr. Papapetropoulos is still employed on such date.
- 11. Granted on December 16, 2022. Vesting to occur on December 16, 2026, provided Mr. Papapetropoulos is still employed on such date.

/s/ Spyridon
Papapetropoulos

07/08/2024

** Signature of Reporting
Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.